Tarsus Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Tarsus Pharmaceuticals's estimated annual revenue is currently $56.7M per year.
- Tarsus Pharmaceuticals's estimated revenue per employee is $215,551
- Tarsus Pharmaceuticals's total funding is $60M.
- Tarsus Pharmaceuticals's current valuation is $429M. (January 2022)
Employee Data
- Tarsus Pharmaceuticals has 263 Employees.
- Tarsus Pharmaceuticals grew their employee count by 119% last year.
Tarsus Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Sr VP, Clinical Affairs | Reveal Email/Phone |
2 | CEO and Chairman | Reveal Email/Phone |
3 | VP, Finance | Reveal Email/Phone |
4 | VP Market Access | Reveal Email/Phone |
5 | VP Medical Affairs | Reveal Email/Phone |
6 | VP Clinical Development | Reveal Email/Phone |
7 | Head Sales Training & Development | Reveal Email/Phone |
8 | VP Sales | Reveal Email/Phone |
9 | VP, Quality | Reveal Email/Phone |
10 | VP, Manufacturing Ops & Supply Chain Management | Reveal Email/Phone |
Tarsus Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $84.8M | 422 | 24% | N/A | N/A |
#2 | $0.4M | 2 | 0% | N/A | N/A |
#3 | $32M | 159 | 3% | N/A | N/A |
#4 | $35M | 121 | 3% | $62.5M | N/A |
#5 | $30.2M | 150 | 18% | N/A | N/A |
#6 | $135.3M | 673 | 0% | N/A | N/A |
#7 | $110.3M | 549 | N/A | N/A | N/A |
#8 | $60.1M | 299 | -4% | N/A | N/A |
#9 | $554.8M | 1725 | 2% | N/A | N/A |
#10 | $10.5M | 52 | 4% | N/A | N/A |
What Is Tarsus Pharmaceuticals?
Tarsus is a late clinical-stage biopharmaceutical company that applies proven science and new technology to revolutionize treatment for patients with unmet needs.
keywords:N/A
$60M
Total Funding
263
Number of Employees
$56.7M
Revenue (est)
119%
Employee Growth %
$429M
Valuation
N/A
Accelerator
Tarsus Pharmaceuticals News
Tarsus Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic...
Checkmate Pharmaceuticals (NASDAQ:CMPI) versus Tarsus Pharmaceuticals (NASDAQ:TARS) Head-To-Head Survey. Posted by admin on Apr 20th, 2022.
Tarsus Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic...
Tarsus Pharmaceuticals, Inc. Announces Positive Results of Saturn-1 Pivotal Trial Evaluating TP-03 for the Treatment of Demodex Blepharitis Saturn-1 Phase 2b/3 trial met all primary and secondary endpoints, and demonstrated significant, clinically meaningful outcomes with no serious treatment-r ...
IRVINE, Calif., May 24, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, toda ...
Other Companies in Irvine
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $78.1M | 263 | 6% | N/A |
#2 | $71.4M | 265 | -5% | N/A |
#3 | $53.5M | 270 | 10% | N/A |
#4 | $53.5M | 270 | 9% | N/A |
#5 | $41.7M | 271 | 3% | N/A |